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Abstract 
The aim of this study was to provide a methodology to make a clear distinction between malignant tumors and 
morphologically similar benign processes, by examining the expression of EGFR, VEGF, HIF1-α, survivin, Bcl-2 
and p53 proteins. Four groups of patient samples were studied: group 1, low-grade astrocytomas (WHO grades I-II) 
(n=6); group 2, peripheral area of high-grade astrocytomas (WHO grades III-IV) (n=5); group 3, gliomatosis cerebri 
(n=11); and group 4, reactive gliosis (n=6). Tissue arrays (TAs) were designed to study apoptosis, angiogenesis and 
invasion-related proteins by immunohistochemistry (IHC). By means of non-parametric analysis (Mann-Whitney U 
test), EGFR staining was shown to be significantly lower in reactive gliosis than in the low- and high-grade 
astrocytomas (p=0.015 and p=0.030, respectively); Bcl-2 immunoreactivity was significantly higher in the 
gliomatosis cerebri samples than in the reactive processes (p=0.005); and finally, Bcl-2 presented significantly lower 
expression levels in reactive gliosis compared to the peripheral areas of high-grade astrocytomas (p=0.004). The 
results indicate that Bcl-2 and EGFR may be useful in conducting differential diagnosis between the above groups, 
while the expression of the remaining antibodies does not appear to aid in distinguishing between the samples 
analyzed. The use of TAs to identify the protein expression profiles of biological markers related to different 
pathways was verified, and its potential as a discriminatory technique for everyday pathology procedures was 
demonstrated. 
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Introduction 
Gliosis is characterized by hypertrophy, proliferation and increased expression of glial fibrillary acidic 
protein, which is a very sensitive indicator of disease processes. Reactive glial cells are therefore of 
fundamental importance to the neuropathologist (1,2). It is debated whether gliomatosis cerebri (GC) is a 
pathologic entity or simply a group of histogenetically diverse tumors related only by a tendency towards 
widespread infiltration (3,4). The unique neuropathological feature of GC is its tendency to be 
paucicellular in most locations, with loss of myelin and preservation of axons; axonal injury occurs late in 
the course of the disease, when increased cell density parallels increased axonal damage (5). GC is a 
specific entity, defined as a diffuse neoplastic glial cell infiltration of the brain that preserves the 
architecture of the normal surrounding tissues (6-8). It has an extremely variable prognosis, thus there is a 
need for molecular markers predictive of its outcome (9). There are few studies on GC in the literature 
due to the scarcity of tumor tissue available for such analysis (8,10-15). 
The relationship between gliomatosis cerebri and common focal gliomas is unclear at present. Due to 
uncertainties concerning the origin and pathogenesis of GC, the current WHO classification includes this 
lesion in a separate section under the category ‘glial tumors of uncertain origin’ (16). The most 
problematic cases of reactive gliosis (RG) from neoplastic glial cell proliferation usually involve small 
fixed-tissue biopsy specimens from stereotactic biopsy, with inadequate morphologic support for 
differentiation using only histological criteria. The peripheral area of high grades of glial neoplasia 
closely resembles that of their cellular proliferation counterparts (17,18). Therefore, pathologists often 
confront a complex diagnostic problem when differentiating between them. Given the importance of 
detailed histopathological evaluation as the necessary first-line technique to resolve this issue, 
complementary microtechniques or other auxiliary methods must be used (19). 
Immunohistochemistry (IHC) was performed on tissue arrays (TAs) allowing for the evaluation of 
molecular targets in a large number of samples in parallel. The 2-mm diameter of the tissue cores 
preserved recognizable histological features, supplying more tissue surface for the evaluation of 
immunostaining (20,21). The importance of differentiating RG from neoplasm cannot be stressed enough, 
since treatment is not only different, but also potentially injurious, if unsuitably applied. Little is known 
regarding the molecular mechanisms that control reactive astrocytosis. Several observations indicate that 
it is a regulated process involving cytokines, inflammatory mediators, growth factors and physiological 
stimuli, such as hypoxia (22). Overexpression of epidermal growth factor receptor (EGFR) occurs in 
reactive astrocytes as a result of a broad range of central nervous system (CNS) insults (23). In the adult 
CNS, the EGFR pathway is absent and is activated following neuronal injury (24,25). 
Neoangiogenesis forms part of any reparative tissue process. Among its regulators, vascular 
endothelial growth factor (VEGF) is highly potent and specific, and acts by activating its related receptors 
on the endothelial cells, resulting in their proliferation, migration and metastasis. VEGF has been 
implicated in most physiological and pathological events (26,22). The up-regulation of VEGF expression 
in response to reduced oxygen tension occurs by means of transcriptional and post-transcriptional 
mechanisms, in which hypoxia-inducible factor 1α (HIF1-α) plays a crucial role. 
To date, IHC to examine p53, Bcl-2 and survivin protein in gliosis and gliomas using TA technology 
is lacking. The difference in p53 protein expression among tumors of grade I and other grades (II-IV) 
may be a plausible explanation for the differences in their biological behaviour. Reactive states should be 
deficient in the glioma-associated mutational damage that we would expect to be present in malignant 
neoplasia.  
Wild-type p53 protein is present in a wide variety of normal cells, but has a very short half-life and is 
present in only low amounts (27), generally below the detection level of immunohistochemical methods. 
Normal brain tissue has not been shown to express p53 immunohistochemically (28). Somatic mutation 
of the p53 gene is a very frequent event in the development of glial neoplasia and, since mutant p53 
proteins are often much more stable than wild-type p53 protein, a high level of mutant p53 protein 
accumulates (27). 
The Bcl-2 proto-oncogene is a member of a growing family of genes that block apoptosis. 
Overexpression of Bcl-2 has also been noted in several glioma lines. Since normal astrocytes do not 
express Bcl-2 protein in vivo, its expression may be indicative of malignant transformation (29). Up-
regulation of Bcl-2 within astrocytes is not uniquely associated with neoplastic transformation, as its 
appearance may also be noted in response to injury to the CNS (30). 
Survivin is a member of the inhibitor of apoptosis protein (IAP) family via a pathway independent of 
Bcl-2, and is also a potent regulator of mitosis. Although survivin has been found to be highly expressed 
in gliomas and is associated with tumorigenesis, progression and the poor prognosis of gliomas (31,32), 
currently the understanding of the relationship between survivin expression and proliferation, apoptosis 
and glioma angiogenesis, as well as its correlation with other biomarkers of malignancy, is limited. 
This report describes an initial investigation of a wide range of known astrocytoma (AC)-related 
markers, with the aim of determining whether they may be applied to address the crucial challenge of 
distinguishing between gliosis and glioma. 
Materials and methods 
Tissue samples. In order to retrospectively evaluate, by means of immunohistochemistry, a variety of AC-
related markers, 28 brain specimens from 26 patients were obtained from the histopathological archives 
of the Department of Pathology of CHUA Coruña (ACoruña, Spain). The samples comprised surgical 
resections or biopsies obtained between 1993 and 2004. The Institutional Review Board of CHUA 
Coruña approved the retrospective review of the medical records and the use of the archived tumor 
specimens. The tumor samples were classified and graded according to the WHO criteria (16). 
Four types of samples were examined, divided into four groups: group 1, low-grade ACs (n=6) 
including 1 pilocytic astrocytoma (PA) specimen (WHO grade I) and 5 ACs (WHO grade II); group 2, 
high-grade ACs (n=5) consisting of 5 specimens from the peripheral area of glioblastoma multiforme 
(GBM) (WHO grade IV); group 3, biopsy specimens from lesions associated with GCs (n=11); group 4, 
biopsy specimens from lesions associated RGs (n=6). Full clinical data were obtained from the 
clinicopathological databases. Viable areas of morphological interest in the specimens were identified by 
a pathologist. A tissue array apparatus (Durviz) was used to obtain tissue cores with a 2-mm diameter for 
the construction of a TA containing 48 samples (a 6x8 matrix was designed). 
To blend together the paraffin wax from the recipient block and the tissue cylinders, the TA was 
incubated at 60˚C for 10 min. After incubation, the tissue cylinders were labelled with the block using a 
glass slide. Sections (4 μm) were obtained using a rotary microtome (Leica RM 2155), mounted on 
silanized slides and incubated until use for IHC. 
Immunohistochemical study. The primary antibodies used are listed in Table I. As indicated in the 
literature, the working dilution was determined using positive controls: for EGFR and p53, epidermoid lip 
carcinoma; for VEGF and survivin, breast carcinoma; for HIF1-α, grade IV glioma; and for Bcl-2, normal 
tonsil tissue. Additional sections, run in parallel with the omission of the primary antibody, served as 
negative controls. 
Table I. Antibodies panel 
Antibody Ig subclass Dilution Incubation Company 
     
EGFR(clone H11) Ig G1 1:25 30’ Dako 
VEGF (C-1) Ig G2a 1:100 30’ Santa Cruz 
HIF1-α (ab8366) Ig G1 1:1,500 Overnight Abcam 
Survivin (D-8) Ig G2a 1:100 Overnight Santa Cruz 
Bcl-2 (clone 124) Ig G1 1:75 30’ Dako 
p53 (clone DO7) Ig G2b 1:500 30’ Dako 
     
 
Dako, Dako Denmark A/S; Santa Cruz, Santa Cruz Biotechnology, Inc.; Abcam, Abcam Ltd., UK. 
 
For IHC, the sections were deparaffinized in xylene and rehydrated in decreasing concentrations of 
ethanol, then washed in deionized water. EGFR antigen retrieval was performed by incubating the 
sections in Proteinase K ready-to-use solution (pH 7.5-7.7) (Dako Denmark A/S) for 5 min; for VEGF, 
survivin and HIF1-α, sections were boiled in a pressure cooker in target retrieval solution (citrate buffer, 
pH 6.0) (Dako) for 25 min; and finally, for Bcl-2 and p53, sections were boiled in a pressure cooker 
(2100 Retriever™, PickCell Laboratories) in 1 mM EDTA(pH 9.0) for 25 min. After cooling, the 
specimens were rinsed three times in deionized water. Sections were then treated with peroxidase 
blocking reagent (ready-to-use) (Dako) for 10 min to eliminate endogenous peroxidase activity. After 
three 30-min washes in phosphate buffered saline (PBS) (pH 7.4) (Sigma) and Tween-20, specific 
primary antibodies were applied at the dilutions shown in Table I. 
After incubation, the slides were washed with PBS and Tween-20. The reaction was visualized using 
the Dako Envision system with diaminobenzidine as the chromogen according to the manufacturer's 
instructions. Finally, the samples were washed again in deionized water, then counterstained with 
hematoxylin, dehydrated and mounted in DePeX (Gurr®). 
Semi-quantification of antibody staining. The immunoreactivity score (IRS) was evaluated by multiplying 
the percentage of positive cells (scored as 0, <1%; 1, 1-24%; 2, 25-49%; 3, 50-74%; and 4, ≥75%) by the 
staining intensity (scored as 1, weak; 2, moderate; and 3, intense staining). 
Statistical analysis. Data are expressed as the mean ± standard deviation (SD). The statistical significance 
of the differences found was evaluated at the 95% confidence level by the non-parametric Mann-Whitney 
U test. p-values <0.05 were considered the cut-off point for significance. Statistical analyses were 
performed using SPSS 15.0 for Windows.  
Results 
EGFR staining. In group 1, no EGFR staining was observed in the PA sample, while the grade IIACs 
showed immunoreactivity to the EGFR monoclonal antibody on the cell membrane of the tumor cells, 
and had the highest IRS score (IRS=3) among the EGFR-stained proteins. In group 2, EGFR expression 
was detected in 83% (5/6) of the peripheral area GBM samples, with the most intense staining in areas of 
high cellular density. Positive staining was not observed in necrotic areas. None of the 11 GC or 6 RG 
samples in groups 3 and 4 exhibited EGFR expression (Fig. 1A-C). 
 
 
 
Figure 1. EGFR staining in (A) group 1, (B) group 2 and (C) group 3. (D) Bcl-2 in GC, IRS=2. (E) Bcl-2 in RG, no reaction. 
Magnification, x40. 
VEGF staining. No VEGF monoclonal antibody staining was observed in the group 1 low-grade AC or 
PA samples. In the group 2 high-grade AC samples, immunoreactivity to VEGF was detected on the 
endothelial cell surface, increasing with vascular proliferation. Cytoplasmic staining of neoplastic cells 
was observed in 40% (2/5) of the group 2 samples, and 54.5% (6/11) of the group 3 GC samples. In the 
group 4 RG specimens, staining was observed in 33.3% (2/6) of the samples in both the cytoplasm of 
reactive astrocytes and in ganglionar cells (Fig. 2A-C).  
  
 
Figure 2. (A) VEGF cytoplasmic staining in group 2 (x20). (B) VEGF in RG, IRS=6 (x40). (C) VEGF in GC, immunoreaction in 
70% of cells (x40); (D) survivin in GC, nuclear reaction in 5% of cells (x40); (E) p53 in RG, nuclear reaction in 25% of cells (x20); 
(F) p53 in GC, nuclear reaction in 5% of cells (x40). 
HIF1-α staining. No HIF1-α staining was observed in the group 1 low-grade AC or PA samples. By 
contrast, positive staining was observed in 60% (3/5) of the group 2 high-grade AC samples, and 36% 
(4/11) of the group 3 GC specimens. None of the group 4 RG samples exhibited HIF1-α expression. 
Survivin staining. Only 20% (1/5) of the samples from the group 2 peripheral area of GBM specimens 
and 18% (2/11) of the group 3 GC samples were observed to be positive for nuclear survivin staining 
(Fig. 2D). 
Bcl-2 staining. Positive staining for Bcl-2 was observed in 50% (3/6) of the group 1 low-grade AC and 
PA samples. In the group 2 high-grade ACs, all the samples were positive for Bcl-2 (clone 124), except 
for one which was assessed as not valuable. Cytoplasmic staining, characterized by a brown reaction in 
the astrocytes and histiocytic cells, was visualized in 72.7% (8/11) of the group 3 GC samples. None of 
the group 4 RG samples exhibited Bcl-2 expression (Fig. 1Dand E). 
p53 staining. A positive nuclear reaction for p53 (clone DO7) was observed in only one group 3 GC and 
one group 4 RG sample (Fig. 2Eand F).  
Expression of markers of invasion, angiogenesis and apoptosis. To further investigate the expression of 
the EGFR, VEGF, HIF1-α, survivin and p53 protein markers in the samples, and in order to identify the 
molecular characteristics that differentiate reactive from neoplastic astrocytes, TA experiments were 
performed using the 28 biopsy specimens from 26 patients. The mean ± SD of the expression of each 
protein is shown in Fig. 3. 
 
 
 
Figure 3. Semi-quantitative analysis of the expression of EGFR, VEGF, HIF1-α, Bcl-2, survivin and p53 antibodies in 28 human 
tissue samples. The X axis represents the pathologic groups analyzed (group 1, low-grade ACs; group 2, peripheral area of high-
grade ACs; group 3, GC; group 4, RG) and the Yaxis represents the mean of the expression values of the antibodies. 
Notably, semi-quantitative analysis of the proteins revealed that Bcl-2 oncoprotein expression was 
statistically lower in the group 4 RG samples compared to the group 2 samples from the peripheral areas 
of GBM (Mann-Whitney U test, p=0.004) and compared to the group 3 GC specimens (p=0.005) (Fig. 4). 
There were no statistically significant differences in Bcl-2 expression (p=0.065) between the group 1 low-
grade AC and group 4 specimens. EGFR intrinsic tyrosine kinase expression was also significantly lower 
in group 4 compared to group 2 (p=0.030) and compared to group 1 (p=0.015) (Figs. 3 and 4). 
 
 
 
Figure 4. Expression of EGFR and Bcl-2. The X axis represents the pathologic groups analyzed (group 1, low-grade ACs; group 2, 
peripheral area of high-grade ACs; group 3, GC; group 4, RG) and the Y axis represents the mean of the semi-quantitative 
expression values for EGFR and Bcl-2, respectively. 
  
No statistically significant differences in the expression of VEGF, HIF1-α, survivin and p53 were 
found among the tissues samples. Consequently, the expression of these molecules assessed 
immunohistochemically does not appear to differentiate astroglial neoplasia from reactive astrogliosis, at 
least in the sample size currently used. 
Discussion 
None of the well-known prognostic factors of gliomas (age, Karnofsky Performance Status, histology 
grading or contrast enhancement) are good predictive indicators in GCs. This may be due in part to the 
small number of patients who present with this lesion, but nevertheless suggests that these prognostic 
markers are less reliable in GC than in common gliomas. Consequently, there is a great need to identify 
novel prognotic factors for GCs. RG is a dynamic event that leads to a densely interwoven glial scar 
composed of numerous cells, including reactive astrocytes, microglia, macrophages and endothelial cells, 
and is accompanied by a neoangiogenic response caused by increased VEGF secretion by quiescent 
reactive astrocytes (22,32,33). 
By means of IHC, VEGF homodimeric glycoprotein immunoreactivity was observed in the form of a 
cytoplasmic staining pattern in the endothelial, nerve and tumoral cells in the four groups included in the 
present study. 
The EGFR pathway controls the phenotypic characteristics of astrocytes. In the developing CNS, 
activation of the EGFR cascade incites astrocyte differentiation. In the adult CNS, the EGFR cascade is 
absent from astrocytes, but is highly up-regulated and activated following neuronal insults (24).  
The activation of EGFR, detected as the phosphorylated form of EGFR by an antibody raised against 
the 170 KD wild-type EGFR and the 145 kD mutant form of the receptor (EGFRVIII), was absent in the 
RG samples studied. EGFR values measured by IHC were significantly higher in groups 1 and 2 than in 
group 4 (Mann-Whitney U test, p=0.015 and p=0.030, respectively). These results suggest that EGFR 
expression is a candidate novel marker that may be useful in the differential diagnosis between reactive 
astrocytes and low-grade or peripheral areas of high-grade gliomas. 
The Bcl-2 mitochondrial oncoprotein, a pro-survival molecule that arrests cells in the G0/G1 phase of 
the cell cycle, is known to be involved in gliomas (34). Bcl-2 is widely expressed during embryogenesis 
within somatic cells, including those of neural origin (35). Thus, it appears to be more strongly expressed 
in cells that are actively differentiating into mature tissues, indicating a role for Bcl-2 in tissue 
morphogenesis and clonal selection. The presence of Bcl-2 in mature neurons has been postulated to 
reflect the effect of neurotrophic factors that help maintain a stable neuronal population (35). 
In the present study, Bcl-2 protein was found to be expressed in all the groups except the group 4 
RGs. The differences in Bcl-2 expression were statistically significant between group 3 and group 4 
(p=0.005). This suggests that Bcl-2 expression is uniquely associated with neoplastic transformation. 
Survivin, another anti-apoptotic protein that operates via a Bcl-2-independent pathway, is a 
structurally unique member of the IAP family that acts as a suppressor of apoptosis, reducing the 
generation of active caspases and playing a central role in cell division. This protein is undetectable in 
normal differentiated tissues (36), but is massively up-regulated in human tumors and is involved in 
cancer progression and treatment resistance. As a result, survivin is currently undergoing extensive 
investigation as a novel therapeutic target (37,38). 
In the present study, nuclear survivin protein expression levels were only detected in groups 2 and 3. 
There was no statistical significance in survivin expression between any of the groups studied. 
IHC for the detection of p53 protein has been used to determine whether it is possible to distinguish 
between malignant tumors and morphologically-similar benign processes. Immunoreactions to DO-7 
among the samples were observed only in the group 3 GCs. Normal p53 protein has a short half-life (5-30 
min) due to its rapid turnover. Mutation of the gene usually leads to the production of a more stable 
protein that can be detected via IHC staining, although a relationship between gene mutations and 
immunoreactivity is not always present (39,40). Despite a variety of existing techniques for the analysis 
of tumor tissue, none of these methods are applicable when using small fixed paraffin-embedded 
specimens, which make up the bulk of pathologic specimens, thus making differentiation difficult. 
The lack of p53 immunoreactivity in a variety of reactive astroglial lesions may help to establish a 
diagnosis in cases hypertrophic astrocytes without atypia or mitosis. Aberrant protein expression in 
human glial tumors is associated with progression from low- to high-grade ACs (41). Therefore, if the TA 
core is immunoreactive with p53 antibodies, a malignant process should be suspected. 
There are discrepancies between the results of our study and previous results, which may be due to the 
use of different methodologies, such as antibody type, antibody specificity, positivity evaluation, 
antigenal retrieval methods and, in glioma samples, genetic heterogeneity (35). 
Several techniques besides histology have been applied to distinguish gliomas from gliosis: 
microsatellite analysis to examine loss of heterozygosity (17), fluorescent in situ hybridization (FISH) 
(42), in situ hybridization (43), comparative genomic hybridization (44,45), RNA microarray expression 
analysis (46), certain proteomic techniques (47) and microdissection techniques, coupled with polymerase 
chain reaction amplification (48). 
The results of the present study indicate that the TA approach designed here has the potential to 
provide discriminating objective information with which to differentiate between RGs and glioma, as it 
permits several areas of tumors to be analyzed using a variety of antibodies. In order to clarify the 
implications of molecular expression on tissue arrays and its differentiating capabilities, further research 
is required. 
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